Cold‐adapted influenza‐vectored RSV vaccine protects BALB/c mice and cotton rats from RSV challenge
Journal of Medical Virology · 2024
DOI: 10.1002/jmv.29308 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medical Virology, 2024. Verfasst von Yongru Xu und 6 weiteren Autor:innen. Beteiligte Einrichtung: The First Medical Center of Chinese PLA General Hospital, Beijing, China. Hauptthemen laut MEDLINE: Mice, Inbred BALB C, Respiratory Syncytial Virus Infections, Respiratory Syncytial Virus Vaccines, Sigmodontinae. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 50 Literaturangaben. Gefördert von: Beijing Natural Science Foundation.
Abstract (Originalsprache)
Respiratory syncytial virus (RSV) remains the primary cause of lower respiratory tract infections, particularly in infants and the elderly. In this study, we employed reverse genetics to generate a chimeric influenza virus expressing neuraminidase‐3F protein conjugate with three repeats of the RSV F protein protective epitope inserted into the NA gene of A/California/7/2009 ca (CA/AA ca), resulting in rFlu/RSV/NA‐3F (hereafter, rFRN3). The expression of NA‐3F protein was confirmed by Western blotting. The morphology and temperature‐sensitive phenotype of rFRN3 were similar to CA/AA ca. Its immunogenicity and protective efficiency were evaluated in BALB/c mice and cotton rats. Intranasal administration of rFRN3 elicited robust humoral, cellular, and to some extent, mucosal immune responses. Compared to controls, rFRN3 protected animals from RSV infection, attenuated lung injury, and reduced viral titers in the nose and lungs post‐RSV challenge. These results demonstrate that rFRN3 can trigger RSV‐specific immune responses and thus exhibits potent protective efficacy. The “dual vaccine” approach of a cold‐adapted influenza vector RSV vaccine will improve the prophylaxis of influenza and RSV infection. rFRN3 thus warrants further clinical investigations as a candidate RSV vaccine.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The First Medical Center of Chinese PLA General Hospital, Beijing, China.
- Faculty of Hepato-Pancreato-Biliary Surgery, Chinese PLA General Hospital, Beijing, China.
- Key Laboratory of Digital Hepatobiliary Surgery, PLA, Institute of Hepatobiliary Surgery of Chinese PLA, Beijing, China.
- Fifth Medical Center of Chinese PLA General Hospital, Beijing, China.
- State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Academy of Military Medical Sciences, Beijing, China.
ORCID-Profile: Penghui Yang
Förderung
- Beijing Natural Science Foundation
Zitieren
APA
Xu, Y., Sun, F., Bai, Z., Bian, C., Wang, X., Zhao, Z., & Yang, P. (2024). Cold‐adapted influenza‐vectored RSV vaccine protects BALB/c mice and cotton rats from RSV challenge. Journal of Medical Virology. https://doi.org/10.1002/jmv.29308
Vancouver
Xu Y, Sun F, Bai Z, Bian C, Wang X, Zhao Z, et al. Cold‐adapted influenza‐vectored RSV vaccine protects BALB/c mice and cotton rats from RSV challenge. Journal of Medical Virology. 2024. doi:10.1002/jmv.29308
BibTeX
@article{Xu2024,
author = {Xu, Yongru and Sun, Fang and Bai, Zhifang and Bian, Chengrong and Wang, Xiliang and Zhao, Zhongpeng and Yang, Penghui},
title = {Cold‐adapted influenza‐vectored RSV vaccine protects BALB/c mice and cotton rats from RSV challenge},
journal = {Journal of Medical Virology},
year = {2024},
doi = {10.1002/jmv.29308}
}
EUVIMED